Solid ganaxolone compositions and methods for the making and use thereof
In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.
1. An intravenous pharmaceutical formulation, comprising solid particles comprising ganaxolone, a hydrophilic polymer, a wetting agent, and an effective amount of a complexing agent, the complexing agent being a small organic molecule having a molecular weight less than 550 and containing a moiety selected from the group consisting of a phenol moiety, an aromatic ester moiety and an aromatic acid moiety, wherein the solid particles have a volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm and the complexing agent is present in an amount from about 0.05% to about 5% w/w based on the weight of the solid particles.
2. The intravenous pharmaceutical formulation of claim 1 , wherein the hydrophilic polymer is in an amount from about 3% to about 50%, w/w, based on the weight of the solid particles.
3. The intravenous pharmaceutical formulation of claim 2 , wherein the wetting agent is in an amount from about 0.01% to about 10%, w/w, based on the weight of the solid particles.
4. The intravenous pharmaceutical formulation of claim 2 , wherein the stabilized particles exhibit an increase in volume weighted median diameter (D50) of not more than about 150% when the particles are dispersed in simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) at a concentration of 0.5 to 1 mg ganaxolone/mL and placed in a heated bath at 36° to 38° C. for 1 hour as compared to the D50 of the stabilized particles when the particles are dispersed in distilled water under the same conditions, wherein the volume weighted median diameter (D50) of the stabilized particles dispersed in SGF or SIF is less than about 750 nm.
5. The intravenous pharmaceutical formulation of claim 1 , wherein the stabilized particles exhibit an increase in volume weighted median diameter (D50) of not more than about 150% when the formulation is dispersed in 15 mL of SGF or SIF at a concentration of 0.5 to 1 mg ganaxolone/mL as compared to the D50 of the stabilized particles when the particles are dispersed in distilled water under the same conditions, wherein the volume weighted median diameter (D50) of the stabilized particles dispersed in SGF or SIF is less than about 750 nm.
6. The intravenous pharmaceutical formulation of claim 1 , wherein the ganaxolone is present in an amount greater than 50% to about 80%, based on the weight of the particles.
7. The intravenous pharmaceutical formulation of claim 6 , wherein the stabilized particles exhibit an increase in volume weighted median diameter (D50) of not more than about 150% when the particles are dispersed in simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) at a concentration of 0.5 to 1 mg ganaxolone/mL and placed in a heated bath at 36° to 38° C. for 1 hour, as compared to the D50 of the stabilized particles when the particles are dispersed in distilled water under the same conditions, wherein the volume weighted median diameter (D50) of the stabilized particles dispersed in SGF or SIF is less than about 750 nm.
8. The intravenous pharmaceutical formulation of claim 1 , wherein the complexing agent is selected from the group consisting of parabens, benzoic acid, methyl anthranilate, phenol, and pharmaceutically acceptable salts thereof and mixtures thereof.
9. The intravenous pharmaceutical formulation of claim 1 , wherein the paraben is selected from the group consisting of methylparaben, ethylparaben, propylparaben, pharmaceutically acceptable salts thereof and mixtures thereof.
10. The intravenous pharmaceutical formulation of claim 1 , wherein the hydrophilic polymer is selected from the group consisting of a cellulosic polymer, a vinyl polymer and mixtures thereof.
11. The intravenous pharmaceutical formulation of claim 10 , wherein the cellulosic polymer is a cellulose ether.
12. The intravenous pharmaceutical formulation intravenous pharmaceutical formulation of claim 10 , wherein the cellulose ether is hydroxypropylmethylcellulose.
13. The intravenous pharmaceutical formulation of claim 10 , wherein the vinyl polymer is polyvinyl alcohol.
14. The intravenous pharmaceutical formulation intravenous pharmaceutical formulation of claim 1 , wherein the wetting agent is selected from the group consisting of sodium lauryl sulfate, a pharmaceutically acceptable salt of docusate, and mixtures thereof.
15. The intravenous pharmaceutical formulation of claim 1 , further comprises an ionic dispersion modulator in an amount from about 1% to about 50%, w/w, based on the weight of the solid particles, wherein the ionic dispersion modulator is an inorganic salt is selected from the group consisting of a magnesium salt, a calcium salt, a lithium salt, a potassium salt, a sodium salt and mixtures thereof or an organic salt is selected from the group consisting of a citrate salt, a succinate salt, a fumarate salt, a malate salt, maleate salt, a tartrate salt, a glutarate salt, a lactate salt and mixtures thereof.
16. The intravenous pharmaceutical formulation of claim 1 , further comprises a water soluble spacer in an amount from about 2% to about 60%, w/w, based on the weight of the solid particles, wherein the water soluble spacer is a saccharide or an ammonium salt.
17. The intravenous pharmaceutical formulation of claim 1 , wherein dosage form provides a therapeutic effect for about 8 to about 24 hours after administration.
18. The intravenous pharmaceutical formulation of claim 1 , wherein the complexing agent comprises methylparaben or a salt thereof.
19. The intravenous pharmaceutical formulation of claim 1 , wherein the complexing agent comprises benzoic acid or a salt thereof.
20. The intravenous pharmaceutical formulation of claim 1 , wherein the complexing agent comprises methyl anthranilate.
21. The intravenous pharmaceutical formulation of claim 1 , wherein ganaxolone is at a dose ranging from about 200 mg to about 800 mg.
22. The intravenous pharmaceutical formulation of claim 1 , wherein the complexing agent stabilizes particle growth after an initial particle growth and endpoint is reached.
23. A method of treating human patients suffering from status epilepticus, comprising intravenously administering to the human patients an effective amount of the intravenous pharmaceutical formulation of claim 1 .
24. An intravenous pharmaceutical formulation, comprising solid particles comprising ganaxolone, a hydrophilic polymer, a wetting agent, and an effective amount of a complexing agent, the complexing agent being a small organic molecule having a molecular weight less than 550 and containing a moiety selected from the group consisting of a phenol moiety, an aromatic ester moiety and an aromatic acid moiety, wherein the stabilized particles have a volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm and the concentration of ganaxolone in the solid stabilized particles is at least 50% by weight.
25. The intravenous pharmaceutical formulation of claim 24 , wherein the ganaxolone is present in an amount greater than 50% to about 80%, based on the weight of the particles.
26. The intravenous pharmaceutical formulation of claim 25 , wherein the complexing agent is selected from the group consisting of parabens, benzoic acid, methyl anthranilate, phenol, and pharmaceutically acceptable salts thereof and mixtures thereof.
27. The intravenous pharmaceutical formulation of claim 26 , wherein the paraben is selected from the group consisting of methylparaben, ethylparaben, propylparaben, pharmaceutically acceptable salts thereof and mixtures thereof.
28. The intravenous pharmaceutical formulation of claim 26 , wherein the complexing agent stabilizes particle growth after an initial particle growth and endpoint is reached.
29. The intravenous pharmaceutical formulation of claim 26 , wherein ganaxolone is at a dose ranging from about 200 mg to about 800 mg.
30. A method of treating human patients suffering from status epilepticus, comprising intravenously administering to the human patients an effective amount of the intravenous pharmaceutical formulation of claim 24 .